ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
1 story in the last 7 days
The latest celcuity news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks celcuity across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Celcuity shares fell after a launch delay overshadowed US approval for the breast cancer drug. The FDA approved the therapy, but a later-than-expected commercial rollout disappointed investors. The stock decline reflects market focus on the timing setback rather than the regulatory milestone.
Summaries by ByteBrief